PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This trial is to describe the safety, tolerability and exposure-toxicity relationship of
Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and
Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone
Phase:
Phase 2
Details
Lead Sponsor:
LegoChem Biosciences, Inc
Collaborators:
Ludwig-Maximilians - University of Munich Radboud University University of California, San Francisco